Istradefylline (Nourianz) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Istradefylline (brand name Nourianz; development code KW-6002) is an oral adenosine A2A receptor antagonist developed by Kyowa Kirin for the treatment of "off" episodes in adults with Parkinson's disease receiving levodopa/carbidopa. It is the first non-dopaminergic drug approved by the FDA for Parkinson's disease in over two decades and represents the first clinical application of adenosine receptor pharmacology in neurodegeneration.[1]
The FDA approved istradefylline on August 27, 2019, as an add-on treatment to levodopa/carbidopa in PD patients experiencing "off" episodes — periods when PD medication is not working optimally and motor symptoms return. Istradefylline had been approved in Japan since 2013, where it was the first adenosine A2A antagonist to reach the market for any indication.[2]
The mechanism of istradefylline is distinct from all other approved PD therapies because it acts on the adenosinergic system rather than the dopaminergic system. Understanding its mechanism requires knowledge of basal ganglia circuit physiology:
In the striatum, medium spiny neurons (MSNs) of the indirect pathway co-express dopamine D2 receptors and adenosine A2A receptors. Under normal conditions, dopamine binding to D2 receptors on these medium spiny neurons inhibits the indirect pathway, facilitating movement. Adenosine, acting at A2A receptors on the same neurons, has the opposite effect — it excites the indirect pathway and thereby suppresses movement.[3]
In Parkinson's disease, the loss of dopaminergic neurons in the substantia nigra pars compacta reduces dopaminergic input to the striatum. This causes:
- Reduced D2 receptor stimulation on indirect pathway MSNs
- Relative overactivity of adenosine A2A signaling (which is no longer counterbalanced by dopamine)
- Excessive activation of the indirect pathway, leading to increased inhibitory output from the globus pallidus internus/subthalamic nucleus circuit
- Motor impairment: bradykinesia, rigidity, and the "off" state[4]
Istradefylline blocks A2A receptors selectively (Ki = 2.2 nM for A2A vs. >1000 nM for A1 receptors), releasing the indirect pathway from the excitatory influence of adenosine. This:
- Restores the balance between the direct and indirect pathways
- Reduces excessive GABAergic output from the indirect pathway
- Improves motor function without directly increasing dopaminergic activity
- Provides a complementary mechanism to levodopa therapy[5]
The non-dopaminergic nature of this mechanism is therapeutically significant because it reduces "off" time without amplifying the peak-dose complications (dyskinesias, hallucinations) associated with increasing dopaminergic stimulation.
At the intracellular level, A2A and D2 receptors form functional heteromers on medium spiny neurons. Adenosine A2A stimulation allosterically reduces D2 receptor affinity for dopamine and opposes D2-mediated intracellular signaling (via opposing effects on adenylyl cyclase and cAMP). By blocking A2A, istradefylline enhances the functional efficacy of dopamine at D2 receptors, synergizing with exogenous dopamine from levodopa therapy.[6]
- Absorption: Rapidly absorbed orally; peak plasma concentration in 1–4 hours. High-fat meals increase exposure by approximately 20% but do not alter efficacy
- Distribution: High protein binding (98%); volume of distribution ~44 L
- Metabolism: Primarily metabolized by CYP3A4 and CYP1A1/1A2. Major metabolite M1 is inactive
- Half-life: Terminal elimination half-life of approximately 46–83 hours, supporting once-daily dosing
- Excretion: Primarily eliminated via hepatic metabolism; renal excretion of unchanged drug is <1%[7]
- CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): Increase istradefylline exposure; maximum dose should not exceed 20 mg/day
- CYP3A4 inducers (e.g., rifampin, carbamazepine): Decrease istradefylline exposure; may reduce efficacy
- Tobacco smoking: Induces CYP1A1/1A2 and may decrease istradefylline levels
- No clinically significant interactions with levodopa/carbidopa, dopamine agonists, or MAO-B inhibitors[7]
- Recommended starting dose: 20 mg once daily as adjunctive therapy to levodopa/carbidopa
- Maximum dose: 40 mg once daily
- Hepatic impairment: Maximum 20 mg/day in moderate hepatic impairment (Child-Pugh B); not recommended in severe impairment
- Available as film-coated tablets (20 mg and 40 mg)[7]
Istradefylline was evaluated in four randomized, double-blind, placebo-controlled Phase III trials enrolling a total of 1,143 participants with Parkinson's disease experiencing ≥2 hours of "off" time daily while on stable levodopa/carbidopa therapy (disease duration average ~9 years).[1]
Study 6002-US-013 (N=231):
- Istradefylline 40 mg/day vs. placebo
- Primary endpoint: Percentage change from baseline in "off" time
- Result: −10.8% (istradefylline) vs. −4.0% (placebo); p=0.03
- Corresponding to −1.8 hours vs. −0.6 hours reduction in daily "off" time
Study 6002-US-018 (N=395):
- Istradefylline 20 mg and 40 mg vs. placebo
- Both doses demonstrated significant reductions in "off" time vs. placebo
Study 6002-009 (Japan, N=373) and Study 6002-US-006 (N=196):
- Consistent direction of effect, with the Japanese study showing robust efficacy
Pooled analysis: Across trials, istradefylline 20–40 mg reduced daily "off" time by approximately 0.7–1.2 hours more than placebo, with corresponding increases in "on" time without troublesome [dyskinesia].[1]
An open-label 52-week extension study demonstrated sustained "off" time reduction and acceptable tolerability with chronic dosing. No evidence of tachyphylaxis or loss of efficacy was observed over the treatment period.[8]
In clinical trials, the most frequently reported adverse events were:
- Dyskinesia (17–18% vs. 8% placebo) — may reflect improved levodopa efficacy rather than direct toxicity
- Dizziness (3%)
- Constipation (4%)
- Nausea (3%)
- Hallucinations (1–3%)
- Insomnia (2%)
- Dyskinesia management: If troublesome dyskinesia occurs, reduction of levodopa dose may be warranted
- Impulse control disorders: Reported in postmarketing experience, as with other PD medications
- Psychiatric symptoms: Hallucinations and psychotic behavior, particularly in elderly patients
- Hepatic: Not recommended in severe hepatic impairment
- Pregnancy: Category C; not studied in pregnant women[9]
Treatment discontinuation due to adverse effects was similar between istradefylline (5–6%) and placebo (5%), indicating good overall tolerability.
In the current PD treatment paradigm, all approved therapies until istradefylline worked by modulating the dopaminergic system — levodopa, dopamine agonists, MAO-B inhibitors, and COMT inhibitors. As Parkinson's disease progresses, motor fluctuations (wearing-off, "off" episodes) become increasingly difficult to manage with dopaminergic optimization alone. Istradefylline provides a non-dopaminergic mechanism to reduce "off" time, particularly valuable when:
- Increasing levodopa dose causes unacceptable dyskinesia or psychiatric side effects
- Dopamine agonists are not tolerated (especially in elderly patients)
- Patients remain with significant "off" time despite optimized dopaminergic therapy[10]
Istradefylline is currently indicated only as adjunctive therapy — not as monotherapy. It is typically added to levodopa/carbidopa regimens in patients with motor fluctuations. Guidelines from the American Academy of Neurology and the Movement Disorder Society include istradefylline as an option for managing motor fluctuations, though long-term comparative studies with other adjunctive therapies are limited.
The approval of istradefylline has stimulated research into other A2A receptor-based approaches:
- Potential cognitive benefits: Preclinical evidence suggests A2A antagonism may have neuroprotective and pro-cognitive effects beyond motor symptom relief
- Application in other neurodegenerative diseases: A2A antagonism is being investigated for potential benefits in Alzheimer's disease (where adenosine signaling is dysregulated), Huntington's disease, and ALS
- Caffeine connection: Epidemiological data showing reduced PD risk with caffeine consumption (a non-selective adenosine receptor antagonist) provided the original rationale for developing selective A2A antagonists[11]
The study of Istradefylline (Nourianz) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Müller et al., The Belated US FDA Approval of the Adenosine A2A Receptor Antagonist Istradefylline for Treatment of Parkinson's Disease, Purinergic Signalling 2020]https://doi.org/10.1007/s11302-020-09694-2)
- [Kondo & Mizuno, A Long-Term Study of Istradefylline Safety and Efficacy in PD, Clinical Neuropharmacology 2015]https://doi.org/10.1097/WNF.0000000000000073)
- [Schiffmann et al., Adenosine A2A Receptors and Basal Ganglia Physiology, Progress in Neurobiology 2007]https://doi.org/10.1016/j.pneurobio.2007.05.001)
- [Schwarzschild et al., Targeting Adenosine A2A Receptors in Parkinson's Disease, Trends in Neurosciences 2006]https://doi.org/10.1016/j.tins.2006.09.004)
- [Jenner et al., Istradefylline — A First Generation Adenosine A2A Antagonist for PD, Expert Review of Neurotherapeutics 2021]https://doi.org/10.1080/14737175.2021.1880896)
- [Fuxe et al., Adenosine A2A–Dopamine D2 Receptor–Receptor Heteromeric Interactions, Biochimica et Biophysica Acta 2007]https://doi.org/10.1016/j.bbamem.2006.09.005)
- [Nourianz Prescribing Information, Kyowa Kirin]https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022075s000lbl.pdf)
- [Bara-Jimenez et al., Adenosine A2A Receptor Antagonist Treatment of Parkinson's Disease, Neurology 2003]https://doi.org/10.1212/01.WNL.0000073152.14867.83)
- [Nourianz Safety Profile — Kyowa Kirin]https://www.nourianzhcp.com/safety/)
- [LeWitt et al., Istradefylline to Treat OFF Episodes in PD, Neurology Clinical Practice 2020]https://doi.org/10.1212/CPJ.0000000000000811)
- [Ascherio et al., Prospective Study of Caffeine Consumption and Risk of PD, Annals of Neurology 2001]https://doi.org/10.1002/ana.1052)